KRAS and neoplasm: Finally, the fact that combined deletion/inhibition of TAK1 and Caspase-8 still blocked transdifferentiation and PDAC development though activation of necroptosis suggests that TAK1 inhibition could still be an effective anti-tumor therapy in PDACs that show a downregulation of the apoptosis machinery in addition to KRAS activation53.